The added value of H2 antagonists in premedication regimens during paclitaxel treatment.
Juul M CoxLeni van DoornRuben MalmbergEsther Oomen-de HoopTessa M BoschPatricia M L A van den BemtIngrid A BoereAgnes JagerRon H J MathijssenRoelof W F van LeeuwenPublished in: British journal of cancer (2021)
www.trialregister.nl ; NL8173.
Keyphrases